Cargando…

Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

PURPOSE: CC-486 is an oral formulation of azacitidine that allows for extended dosing schedules to prolong azacitidine exposure to malignant cells and maximize clinical activity. CC-486 300 mg daily, administered for 14 or 21 days of 28-day treatment cycles, is currently under investigation in two o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Babiker, Hani M., Milhem, Mohammed, Aisner, Joseph, Edenfield, William, Shepard, Dale, Savona, Michael, Iyer, Swaminathan, Abdelrahim, Maen, Beach, C. L., Skikne, Barry, Laille, Eric, Tsai, Kao-Tai, Ho, Thai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036073/ https://www.ncbi.nlm.nih.gov/pubmed/32036412 http://dx.doi.org/10.1007/s00280-020-04037-9

Ejemplares similares

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies
por: Savona, Michael R., et al.
Publicado: (2018)

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
por: Garcia-Manero, G, et al.
Publicado: (2016)

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
por: Garcia-Manero, Guillermo, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
por: Laille, Eric, et al.
Publicado: (2015)

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
por: Roboz, Gail J, et al.
Publicado: (2016)

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
por: de Lima, Marcos, et al.
Publicado: (2018)

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL
por: Martin, Peter, et al.
Publicado: (2022)

A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
por: Heumann, Thatcher R., et al.
Publicado: (2022)

Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects
por: Lv, Yuan, et al.
Publicado: (2020)

In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine
por: Chen, Yong, et al.
Publicado: (2010)

Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
por: Ramsey, Haley E., et al.
Publicado: (2020)

Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia
por: Garcia-Manero, Guillermo, et al.
Publicado: (2016)

Allicin Bioavailability and Bioequivalence from Garlic Supplements and Garlic Foods
por: Lawson, Larry D., et al.
Publicado: (2018)

Alternative Analysis Approaches for the Assessment of Pilot Bioavailability/Bioequivalence Studies
por: Henriques, Sara Carolina, et al.
Publicado: (2023)

Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets: A meta-analysis of pharmacokinetic, bioavailability, or bioequivalence studies
por: Sun, Ming-Li, et al.
Publicado: (2023)

Comparative assessment of saliva and plasma for drug bioavailability and bioequivalence studies in humans
por: Idkaidek, Nasir M.
Publicado: (2017)

Predictive Potential of C(max) Bioequivalence in Pilot Bioavailability/Bioequivalence Studies, through the Alternative ƒ(2) Similarity Factor Method
por: Henriques, Sara Carolina, et al.
Publicado: (2023)

Relative Bioavailability and Bioequivalence of Brivaracetam 10 mg/mL Oral Solution and 50‐mg Film‐Coated Tablet
por: Otoul, Christian, et al.
Publicado: (2016)

Pharmacokinetics and Bioequivalence Evaluation of Cyclobenzaprine Tablets
por: Brioschi, Tatiane Maria de Lima Souza, et al.
Publicado: (2013)

A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets
por: Arora, Rachna, et al.
Publicado: (2016)

Size-reduced fexuprazan 20 mg demonstrated the optimal bioavailability and bioequivalence with the reference formulation
por: Yang, A-Young, et al.
Publicado: (2023)

Comparison of Bioavailability and Bioequivalence of Generic and Brand Name Formulations of Escitalopram Oxalate Tablets in Healthy Chinese Population Under Fasting and Fed Conditions
por: Li, Qiuying, et al.
Publicado: (2020)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
por: Taylor, Kirsty, et al.
Publicado: (2020)

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
por: Döhner, Hartmut, et al.
Publicado: (2018)

Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine‐Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study
por: Sun, Lei, et al.
Publicado: (2018)

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
por: Wei, Andrew H., et al.
Publicado: (2023)

Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate
por: Hussaini, Azra, et al.
Publicado: (2017)

Combined Methodologies for Determining In Vitro Bioavailability of Drugs and Prediction of In Vivo Bioequivalence From Pharmaceutical Oral Formulations
por: De Simone, A., et al.
Publicado: (2021)

Bioequivalence Study of Modified-Release Gliclazide Tablets in Healthy Volunteers
por: Rojanasthien, Noppamas, et al.
Publicado: (2012)

Bioequivalence Study of Donepezil Hydrochloride Tablets in Healthy Male Volunteers
por: Rojanasthien, Noppamas, et al.
Publicado: (2012)

Bioequivalence of perampanel fine granules and tablets in healthy Japanese subjects
por: Shiba, Sari, et al.
Publicado: (2020)

Development and bioequivalence study of potassium chloride extended release tablets
por: Le Thi, Thu Van, et al.
Publicado: (2018)

Bioequivalence of two tablet formulations of cefpodoxime proxetil in beagle dogs
por: Gao, Yan-Yan, et al.
Publicado: (2022)

Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies
por: Chen, Cuiping, et al.
Publicado: (2021)

Trapezoid bioequivalence: A rational bioavailability evaluation approach on account of the pharmaceutical‐driven balance of population average and variability
por: Soufsaf, Sara, et al.
Publicado: (2022)

Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors
por: Sharma, Shringi, et al.
Publicado: (2022)

Bioequivalence of the 4-mg Oral Granules and Chewable Tablet Formulations of Montelukast
por: Knorr, Barbara, et al.
Publicado: (2010)

Quality Attributes and In Vitro Bioequivalence of Different Brands of Amoxicillin Trihydrate Tablets
por: Al-Tabakha, Moawia M., et al.
Publicado: (2017)

In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software
por: Wang, Lu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pi96db3s5clitok54g8gcv04a5